The inspection of the company's API facility in Mekaguda has been successfully completed by the United States Food and Drug Administration (USFDA).
The inspection was conducted during February 12-16, 2018, it added.
The regulatory audit resulted in zero observations and no Form 483 was issued, Natco Pharma said.
Form 483 is issued by the USFDA if it finds objectionable conditions at a facility.
Disclaimer: No Business Standard Journalist was involved in creation of this content